Drugs.com - Clinical Trials

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130...

Jun 3, 2025 - 22:55
 0
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130...
Read More

Tags:

Previous Article

Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Trea...

Next Article

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for ...

Related Posts

Bristol Myers Squibb Provides Update on Camzyos Phase 3 ODYSSEY-HCM Trial

Bristol Myers Squibb Provides Update on Camzyos Phase 3...

May 12, 2025  0

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Granted U.S. FDA Breakthrough Therapy Designa...

Jun 5, 2025  0

Combination Immunotherapy Shrank a Variety of Metastatic Gastrointestinal Cancers

Combination Immunotherapy Shrank a Variety of Metastati...

May 12, 2025  0